|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
1/24/2006 2:11:57 PM
(January 23, 2006) – The Theramed Corporation (“Theramed” or the “Company”) announced today that it has entered into a License and Distribution Agreement with Nature’s Plus, a division of EMS Sigma Pharma for the Sigmasporin® (cyclosporine) product line. EMS Sigma Pharma is the second largest locally-owned Brazilian pharmaceutical company with over $600 million in annual sales and a rapidly expanding European operation. Bourne Partners served as Theramed’s exclusive financial advisor in this transaction.
Theramed will seek approval to market Sigmasporin® as a prophylactic against organ rejection in kidney, liver, and heart allogeneic transplants, as a potential treatment for patients with severe active rheumatoid arthritis, and in the treatment of adult nonimmunocompromised patients with severe, recalcitrant, plaque psoriasis. Sigmasporin® is bioequivalent Canada’s leading cyclosporine product, Neoral®, which is marketed by Novartis Pharmaceuticals Canada, Inc. According to IMS Health data for the Canadian market, Neoral® sales in 2004 were estimated at approximately C$40 million. In the United States, sales of all cyclosporine products were in excess of $235 million in 2004.
Theramed plans to market Sigmasporin® in 25mg, 50mg and 100mg strengths...More.
|
|
|
|
|
|
|
|
|
|
|